BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Azixa verubulin: Phase IIb started

Myrexis began a U.S. and Indian Phase IIb trial to compare once-weekly Azixa given for the first 3 weeks of a 28-day cycle with standard of care (SOC) vs. SOC alone...

Read the full 131 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >